Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Anti-cholesterol statins do not reduce reproductive hormones in women of child-bearing age

02.01.2003


Physicians have been concerned that relatively new prescription medications called statins, which are being increasingly prescribed to reduce blood cholesterol levels, might also decrease reproductive hormone levels and cause women of child-bearing age to be less fertile.



A study headed by researchers at Cedars-Sinai Medical Center in Los Angeles found that neither the use of statins nor low blood cholesterol levels significantly affected reproductive hormone levels in pre-, peri-, or postmenopausal women. These findings are the subject of an article appearing in the current issue of the American Journal of Medicine.

Specialists in heart disease and stroke typically urge patients to maintain low levels of low-density lipoproteins (LDL) and total cholesterol in the blood, but a certain amount of cholesterol is necessary. In fact, reproductive hormones are derivatives of cholesterol, which led researchers to wonder if statins, which reduce blood cholesterol, might also reduce reproductive hormones.


According to C. Noel Bairey Merz, M.D., the report’s first author and the primary investigator of the WISE Study, "Although statins have been shown to be safe in clinical trials, fewer than 20 percent of trial participants have been women, and previous studies of the impact on reproductive hormones did not include premenopausal women of childbearing age."

Dr. Bairey Merz is director of Cedars-Sinai’Medical Center’s Preventive and Rehabilitative Cardiac Center, and director of the Women’s Health Program. She also holds the Women’s Guild Chair in Women’s Health at Cedars-Sinai.

The new study included 453 women with coronary risk factors who were undergoing coronary angiography for suspected ischemia – lack of oxygen to the heart – at four academic medical centers in the United States. Of the total, 114 women were premenopausal. Data analyzed were drawn from an ongoing study, the Women’s Ischemia Syndrome Evaluation (WISE), sponsored by the National Heart, Lung and Blood Institute.

"Neither blood lipoprotein level nor use of statins was a significant independent predictor of reproductive hormone levels in models that adjusted for age, menopausal status, menstrual phase, and body mass index," according to the article.

Although the results offer more reassurance that statin use is safe, Dr. Bairey Merz noted that the women in this sample were undergoing testing for suspected myocardial ischemia and may not be representative of the general population. She said additional large-scale studies that would further reduce potential variables should be conducted, focusing particularly on women in their child-bearing years.


The work was supported by The Women’s Guild of Cedars-Sinai Medical Center; The National Heart, Lung and Blood Institute (contracts N01-HV-68161, N01-HV-68162, N01-HV-68163, and N01-HV-68164); a General Clinical Research Center grant MO1-RR00425 from the National Center for Research Resources, Bethesda, Md.; a grant from the Gustavus and Louis Pfeiffer Research Foundation, Danville, N.J.; and a grant from The Ladies Hospital Aid Society of Western Pennsylvania, Pittsburgh.

Cedars-Sinai Medical Center is one of the largest nonprofit academic medical centers in the Western United States. For the fifth straight two-year period, it has been named Southern California’s gold standard in health care in an independent survey. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthrough in biomedical research and superlative medical education. Named one of the 100 "Most Wired" hospitals in health care in 2001, the Medical Center ranks among the top 10 non-university hospitals in the nation for its research activities.

IRB #2398 Women’s Ischemic Symptom Evaluation (WISE) - Blood Hormone Level Determination

CITATION: American Journal of Medicine, December 2002, Volume 113, Number 9, "Cholesterol-Lowering Medication, Cholesterol Level, and Reproductive Hormones in Women: The Women’s Ischemia Syndrome Evaluation (WISE)."


Sandra Van | Van Communications
Further information:
http://www.csmc.edu/

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>